Vaxcyte Inc. (PCVX): Price and Financial Metrics

Vaxcyte Inc. (PCVX): $68.76

0.51 (-0.74%)

POWR Rating

Component Grades








PCVX Price/Volume Stats

Current price $68.76 52-week high $82.04
Prev. close $69.27 52-week low $44.20
Day low $68.51 Volume 480,300
Day high $69.84 Avg. volume 791,961
50-day MA $65.89 Dividend yield N/A
200-day MA $59.63 Market Cap 7.48B

PCVX Stock Price Chart Interactive Chart >

Vaxcyte Inc. (PCVX) Company Bio

Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.

PCVX Latest News Stream

Event/Time News Detail
Loading, please wait...

PCVX Latest Social Stream

Loading social stream, please wait...

View Full PCVX Social Stream

Latest PCVX News From Around the Web

Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares

Vaxcyte Inc (NASDAQ:PCVX), a company specializing in vaccine innovation with a focus on improving global health through the development of superior vaccines, has reported an insider selling event.

Yahoo | December 21, 2023

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | December 8, 2023

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- -- Results Confirm Potential of Carrier-Sparing, Cell-Free Platform Technology Underlying VAX-24 -- -- Topline Data from the VAX-24 Phase 3 Pivotal Non-Inferiority Study in Adults Expected in 2025 -- SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Va

Yahoo | December 4, 2023

Vaxcyte Appoints Jacks Lee to Board of Directors

SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. “We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte’s Board of Directors as we continue to reali

Yahoo | November 28, 2023

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 -- SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc

Yahoo | November 27, 2023

Read More 'PCVX' Stories Here

PCVX Price Returns

1-mo 13.24%
3-mo -12.93%
6-mo 37.30%
1-year 40.41%
3-year 212.55%
5-year N/A
YTD 9.49%
2023 30.97%
2022 101.56%
2021 -10.46%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!